GURUFOCUS.COM » STOCK LIST » USA » NYSE » Biohaven Ltd (NYSE:BHVN) » Definitions » Total Liabilities
Switch to:

Biohaven (NYSE:BHVN) Total Liabilities

: $35.43 Mil (As of Sep. 2022)
View and export this data going back to 2022. Start your Free Trial

Biohaven's Total Liabilities for the quarter that ended in Sep. 2022 was $35.43 Mil.

Biohaven's quarterly Total Liabilities increased from Dec. 2021 ($47.37 Mil) to Jun. 2022 ($70.58 Mil) but then declined from Jun. 2022 ($70.58 Mil) to Sep. 2022 ($35.43 Mil).

Biohaven's annual Total Liabilities increased from . 20 ($0.00 Mil) to Dec. 2020 ($34.72 Mil) and increased from Dec. 2020 ($34.72 Mil) to Dec. 2021 ($47.37 Mil).


Biohaven Total Liabilities Historical Data

The historical data trend for Biohaven's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biohaven Annual Data
Trend Dec20 Dec21
Total Liabilities
34.72 47.37

Biohaven Quarterly Data
Dec20 Jun21 Sep21 Dec21 Jun22 Sep22
Total Liabilities Premium Member Only - - 47.37 70.58 35.43

Biohaven Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Biohaven's Total Liabilities for the fiscal year that ended in Dec. 2021 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=41.935+(0+5.435
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=47.37

Total Liabilities=Total Assets (A: Dec. 2021 )-Total Equity (A: Dec. 2021 )
=142.061-94.691
=47.37

Biohaven's Total Liabilities for the quarter that ended in Sep. 2022 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=28.435+(0+6.995
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=35.43

Total Liabilities=Total Assets (Q: Sep. 2022 )-Total Equity (Q: Sep. 2022 )
=135.646-100.216
=35.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biohaven Total Liabilities Related Terms

Thank you for viewing the detailed overview of Biohaven's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Biohaven (NYSE:BHVN) Business Description

Biohaven logo
Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
Biohaven Ltd is a commercial-stage biopharmaceutical company with a portfolio of innovative therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven's Neuroinnovation portfolio includes FDA-approved Nurtec ODT (rimegepant) for the acute and preventive treatment of migraine (EMA-approved as Vydura (rimegepant) for the acute treatment of migraine with or without aura, and prophylaxis of episodic migraine.
Executives
Robert J Hugin director C/O THE MEDICINES CO 8 CAMPUS DR PARSIPPANY NJ 07054
Michael Thomas Heffernan director C/O CORNERSTONE THERAPEUTICS INC. 1255 CRESCENT GREEN DRIVE, SUITE 250 CARY NC 27518
Julia P Gregory director 8800 TECHNOLOGY FOREST PLACE THE WOODLANDS TX 77381
Gregory Bailey director 4 A CHESHAM STREET LONDON X0 SW1X8DT
Kimberly Gentile officer: SVP, Clinical Operations C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
John W Childs director 111 HUNTINGTON AVENUE SUITE 2900 BOSTON MA 02199
Vlad Coric director, officer: Chief Executive Officer C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Irina Antonijevic director 215 CHURCH STREET NEW HAVEN CT 06510
Matthew Buten officer: Chief Financial Officer 215 CHURCH STREET NEW HAVEN CT 06510
Kishan Mehta director 540 WEST 49TH STREET UNIT# PH1N NEW YORK NY 10019
Biohaven Pharmaceutical Holding Co Ltd. 10 percent owner 215 CHURCH STREET NEW HAVEN CT 06510
Bruce Car officer: Chief Scientific Officer AGIOS PHARMACEUTICALS, INC. 88 SIDNEY STREET CAMBRIDGE MA 02139

Biohaven (NYSE:BHVN) Headlines

From GuruFocus

Other Sources

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
premium membership